

29 October 2014

## **ASX ANNOUNCEMENT**

### **ANALYTICA PREPARES FOR PERICOACH CLINICAL TRIAL**

- **Multi-site Study Protocol being submitted for Ethics Approvals**
- **Study of PeriCoach® Efficacy in Stress Urinary Incontinence and Sexual Function**

Analytica Ltd (ASX:ALT) is pleased to announce that it has completed the design of the Clinical Trial for the PeriCoach® system.

This multi-centre, randomised, controlled study intends to evaluate the efficacy of the PeriCoach system in females with stress urinary incontinence compared to unassisted pelvic floor exercise as well as the degree of user satisfaction in terms of outcome, ease of use, and improvement in sexual function.

The Principal Investigator will be Dr Ailsa Wilson Edwards, a Urologist at Continence Matters at Calvary North Adelaide Hospital and member of Analytica's Australian Clinical Advisory Board. The study CRO partner is Five Corners Pty Ltd.

Pending ethics committee clearances, the study aims to use 100 participants at up to 10 sites in Australia, with evaluations conducted at baseline, device training and implementation, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks post initial usage of the PeriCoach device.

This study is not required for any regulatory approvals and is being undertaken to provide clinicians and other partners with formal evidence of the system's efficacy.

For, and on behalf of the Board,

**Dr Michael Monsour**

Chairman, Board of Directors

## *About Analytica Limited*

*Analytica's lead product is the PeriCoach™ System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.*

*PeriCoach™ comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is correctly performing pelvic floor exercises and if these are improving her condition; otherwise physicians are guided on the need for surgery.*

*PeriCoach™ has been approved in Australia with product launches expected in 2014 in Australia, and Europe and the US in 2015. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence.*

